The following articles (labelled with PubMed ID or TBD) are for your review
||Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
||Takeda California, Inc.
||Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
||Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).
||Icahn School of Medicine at Mount Sinai
||Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
||Universit£ degli Studi di Parma
||A quantitative analysis of kinase inhibitor selectivity.
||Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).
||Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066).
||Bristol-Myers Squibb Research and Development
||Comprehensive analysis of kinase inhibitor selectivity.
||Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity.
||AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
||Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
||University of Zurich
||Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.